Home
/
Conditions
/ Sarcopenia
Longevity and Aging
Schedule a Consultation
Sarcopenia
Sarcopenia is the progressive loss of skeletal muscle mass, strength, and function that accelerates with aging and is compounded by hormonal decline, insulin resistance, chronic inflammation, and sedentary behavior. It is the single strongest predictor of functional decline, fall risk, fracture, loss of independence, and all-cause mortality in aging adults. Conventional medicine treats sarcopenia reactively after falls and fractures occur. Functional medicine identifies the hormonal, metabolic, and inflammatory drivers producing the muscle loss and intervenes before disability develops.
Longevity and AgingMuscle and Functional DeclinePreventable and Reversible
3 to 8%muscle mass lost per decade after age 30, accelerating after 60
#1 Predictorof functional decline, fall risk, and loss of independence in aging
Reversiblewhen hormonal, metabolic, and nutritional drivers are identified and corrected
← Back to Conditions
Condition: Sarcopenia | Category: Longevity and Aging | Reviewed by: Brian Lamkin, DO
What Is Sarcopenia?
Sarcopenia is the progressive, age-associated loss of skeletal muscle mass, strength, and physical function. It begins as early as the fourth decade of life, with 3 to 8 percent of muscle mass lost per decade after age 30, accelerating significantly after age 60. By age 80, the average adult has lost 30 to 40 percent of their peak muscle mass. More critically than the mass loss, sarcopenia produces disproportionate strength loss: strength declines 2 to 5 times faster than mass, reflecting the loss of type II (fast-twitch) muscle fibers, neuromuscular junction deterioration, and impaired muscle quality from fat infiltration (myosteatosis).
Sarcopenia is the single strongest predictor of functional decline, fall risk, fracture, hospitalization, loss of independence, and all-cause mortality in aging adults. It is more predictive of mortality than cardiovascular disease, obesity, or cancer independently. Yet it is rarely screened for, rarely diagnosed, and rarely treated proactively. The drivers are identifiable: hormonal decline (testosterone, growth hormone, IGF-1), insulin resistance producing anabolic resistance, chronic inflammation, mitochondrial dysfunction, vitamin D deficiency, inadequate protein intake, and absence of resistance training.
Key principle: Sarcopenia is not an inevitable consequence of aging. It is a condition with identifiable, measurable, and treatable biological drivers. When hormonal status, insulin sensitivity, inflammatory burden, vitamin D, and protein intake are optimized alongside progressive resistance training, muscle mass and strength are recoverable at any age. The question is not whether sarcopenia can be reversed but whether the drivers are being identified and treated.
Why Sarcopenia Matters
Mortality and Functional Impact
- All-cause mortality: sarcopenia increases all-cause mortality by 2 to 4 fold independent of age, sex, and comorbidities
- Fall risk and fracture: reduced muscle strength and balance impairment produce falls that result in hip fracture, the most devastating single event in geriatric medicine (20 to 30 percent 1-year mortality)
- Loss of independence: inability to rise from a chair, climb stairs, carry groceries, or perform daily activities leads to assisted living placement
- Hospitalization: sarcopenic patients have longer hospital stays, more complications, and higher readmission rates for any cause
Why Standard Medicine Misses It
- Sarcopenia is not routinely screened: there is no standard screening protocol in primary care despite its mortality impact exceeding most conditions that are screened
- BMI masks sarcopenia: a patient can have normal or elevated BMI while being profoundly sarcopenic (sarcopenic obesity) because fat replaces muscle without changing weight
- Hormonal evaluation is not connected to muscle: testosterone decline is acknowledged but not treated as a modifiable sarcopenia driver
- The protein RDA is inadequate for muscle maintenance: the RDA of 0.8g/kg/day prevents deficiency but is insufficient for muscle protein synthesis in adults over 40
Common Symptoms
Strength and Function
- Difficulty rising from a chair without using arms
- Reduced grip strength
- Slower walking speed
- Difficulty climbing stairs
Physical Changes
- Visible muscle wasting in arms and legs
- Increased body fat despite stable or declining weight
- Reduced balance and coordination
- Increased fall frequency
Metabolic Signals
- Fatigue and reduced stamina
- Poor recovery from illness or surgery
- Worsening blood sugar control (muscle is the largest glucose sink)
- Declining bone density (muscle and bone share hormonal and mechanical drivers)
Root Causes: A Functional Medicine Perspective
Sarcopenia is not a single mechanism. It is the convergence of multiple biological drivers that shift the balance from muscle protein synthesis toward muscle protein breakdown.
Hormonal Decline
Testosterone is the primary anabolic hormone for skeletal muscle. It stimulates muscle protein synthesis, activates satellite cells for muscle repair and growth, and opposes cortisol's catabolic effects. Andropause in men and menopause in women produce testosterone decline that directly reduces the anabolic stimulus maintaining muscle mass. Growth hormone and IGF-1 decline compound this effect. DHEA decline reduces the precursor pool for local tissue androgen production.
Insulin Resistance and Anabolic Resistance
Insulin resistance produces anabolic resistance: the muscle's ability to respond to dietary protein by synthesizing new muscle protein is blunted. An insulin-resistant 60-year-old eating the same protein as an insulin-sensitive 30-year-old will synthesize significantly less muscle protein from the same meal. This means that insulin sensitization is a muscle-building intervention: improving insulin sensitivity restores the muscle's ability to use dietary protein for growth. Fasting insulin and HOMA-IR identify this mechanism.
Chronic Inflammation (Inflammaging)
Chronic low-grade inflammation (elevated IL-6, TNF-alpha, hs-CRP) drives muscle protein breakdown through the ubiquitin-proteasome pathway. This "inflammaging" accelerates sarcopenia independently of hormonal and nutritional status. Anti-inflammatory intervention (omega-3 fatty acids, curcumin, gut health optimization) directly reduces the catabolic inflammatory signaling that breaks down muscle.
Vitamin D Deficiency and Mitochondrial Dysfunction
Vitamin D receptors are expressed in skeletal muscle. Vitamin D deficiency impairs type II muscle fiber function, reduces satellite cell activity, and increases fall risk through both muscle weakness and impaired neuromuscular coordination. Mitochondrial dysfunction reduces the energy production capacity of muscle cells, producing fatigue and impaired contractile function independently of muscle mass.
Conventional vs Functional Medicine Approach
| Domain | Conventional Medicine | Functional Medicine |
|---|---|---|
| Screening | Not routinely performed | Grip strength, gait speed, body composition (DEXA), and laboratory assessment of drivers |
| Treatment | "Exercise more and eat protein" (general advice) | Progressive resistance training prescription plus hormone optimization, insulin sensitization, protein dosing (1.2 to 1.6g/kg/day), vitamin D repletion, creatine, anti-inflammatory protocols |
| Hormones | Not evaluated as muscle driver | Testosterone, IGF-1, DHEA-S evaluated and optimized when deficient |
| Technology | Not utilized | BTL Emsculpt NEO for neuromuscular stimulation and muscle hypertrophy in patients unable to perform adequate resistance training |
Key Labs to Evaluate
Free TestosteroneThe biologically active anabolic signal driving muscle protein synthesis.
→IGF-1Growth hormone axis marker. Low IGF-1 identifies anabolic insufficiency.
→Fasting InsulinInsulin resistance produces anabolic resistance. Sensitization restores muscle protein synthesis.
→Vitamin DDeficiency impairs type II fiber function, satellite cell activity, and neuromuscular coordination.
→hs-CRPInflammatory burden driving muscle protein breakdown through catabolic pathways.
→How to Interpret These Labs Together
Low free testosterone with low IGF-1 and elevated fasting insulin identifies the triple-driver sarcopenia pattern: hormonal anabolic insufficiency (reduced synthesis stimulus), anabolic resistance (impaired response to dietary protein), and growth hormone axis decline (reduced satellite cell activation). Testosterone optimization, insulin sensitization, and protein dosing at 1.6g/kg/day address all three mechanisms simultaneously.
Normal hormones with elevated hs-CRP and low vitamin D identifies the inflammatory-nutritional pattern: muscle breakdown is being accelerated by inflammatory signaling while vitamin D deficiency impairs the fiber function and neuromuscular coordination that resist the decline. Anti-inflammatory protocols plus vitamin D repletion to 60 to 80 ng/mL address this pattern without requiring hormonal intervention.
Common Patterns Seen in Patients
- The 62-year-old who "just feels weaker" and is told it is aging: Progressive strength decline over 3 years. Difficulty rising from low chairs. Falls twice in 6 months. Free testosterone in the lower 5th percentile. IGF-1 low. Fasting insulin 16. Vitamin D 22. Every major sarcopenia driver was active and none had been evaluated. Testosterone optimization, insulin sensitization, vitamin D repletion, protein increase to 1.4g/kg/day, and progressive resistance training prescription. Grip strength improved 35 percent in 4 months. Falls stopped.
- The post-menopausal woman with "osteoporosis" who actually has sarcopenia driving the fracture risk: DEXA for bone density revealed osteopenia. Started on bisphosphonate. Muscle mass on the same DEXA was in the sarcopenic range but was never mentioned. The bone loss and the muscle loss share the same hormonal and mechanical drivers. Bone density improves when muscle is restored because resistance training loads bone. Treating the sarcopenia treats the osteoporosis through the same intervention.
- The sarcopenic obese patient with normal BMI: BMI 26 (normal-overweight). Body composition: 38 percent body fat, muscle mass in the 10th percentile for age. This is sarcopenic obesity, the highest-risk phenotype, masked by normal weight because fat has replaced muscle. Fasting insulin 20, hs-CRP 3.4. Metabolic intervention targeting insulin resistance plus progressive resistance training reversed the body composition over 8 months.
Treatment and Optimization Strategy
Multi-Mechanism Sarcopenia Reversal
Exercise and Nutrition
- Progressive resistance training 3 to 4 days per week: the single most powerful sarcopenia intervention. Compound movements (squat, deadlift, press, row) with progressive overload targeting type II fibers
- Protein 1.2 to 1.6g/kg/day: distributed across 3 to 4 meals with 30 to 40g per meal. Leucine-rich sources (whey, eggs, meat) to maximize muscle protein synthesis per meal
- Creatine monohydrate 3 to 5g daily: enhances muscle energy (phosphocreatine), increases satellite cell activation, improves strength gains from resistance training, and has neuroprotective benefits
- BTL Emsculpt NEO: supramaximal neuromuscular stimulation producing 20,000 contractions per session for patients unable to perform adequate resistance training due to mobility limitations, joint disease, or deconditioning
Hormonal and Metabolic
- Testosterone optimization: bioidentical testosterone replacement when free testosterone is confirmed low, with monitoring of hematocrit, PSA, estradiol, and lipids
- Insulin sensitization: reduces anabolic resistance and restores the muscle's ability to use dietary protein for synthesis. Berberine, time-restricted eating, and resistance training are the most effective strategies
- Vitamin D optimization (60 to 80 ng/mL): restores type II fiber function, satellite cell activity, and neuromuscular coordination
- Anti-inflammatory protocols: omega-3 (3 to 4g EPA+DHA), curcumin for NF-kB inhibition, and gut health optimization to reduce the inflammaging driving muscle breakdown
What Most Doctors Miss
- Sarcopenia is not screened for: it is more predictive of mortality than cardiovascular disease, yet there is no standard screening protocol. Grip strength and gait speed take 2 minutes and provide more prognostic information than many standard lab panels.
- BMI masks sarcopenic obesity: the highest-risk phenotype (low muscle, high fat) has normal BMI because fat replaces muscle at similar weight. Body composition, not weight, determines risk.
- Hormonal evaluation is not connected to muscle: testosterone and IGF-1 decline are documented but not treated as modifiable sarcopenia drivers. Hormonal optimization is a muscle intervention.
- The protein RDA is insufficient for muscle maintenance: 0.8g/kg/day prevents protein deficiency but is 50 percent below the intake needed for muscle protein synthesis in adults over 40. This single dietary recommendation contributes to sarcopenia at scale.
When to Seek Medical Care
If you are over 50 and notice declining strength, difficulty with functional tasks (rising from chairs, climbing stairs, carrying objects), increased fall frequency, or progressive fatigue, a comprehensive evaluation of the hormonal, metabolic, inflammatory, and nutritional drivers of muscle loss is warranted. Do not accept "this is just aging" as a diagnosis.
Recommended Testing
Sarcopenia evaluation identifies the specific hormonal, metabolic, and inflammatory drivers producing muscle loss and guides targeted intervention.
Hormonal
- Free and Total Testosterone
- IGF-1
- DHEA-S
- SHBG
Metabolic and Inflammatory
- Fasting Insulin / HOMA-IR
- hs-CRP
- Vitamin D
- HbA1c
Need metabolic and inflammatory testing alongside hormones?
Explore All Testing Options →Frequently Asked Questions
What is sarcopenia?
Sarcopenia is the progressive loss of skeletal muscle mass, strength, and function that accelerates with aging. It is the strongest predictor of functional decline, fall risk, and all-cause mortality in aging adults. It is driven by identifiable hormonal, metabolic, and inflammatory mechanisms that are treatable.
Can sarcopenia be reversed?
Yes. Progressive resistance training combined with protein optimization, hormonal restoration when deficient, vitamin D repletion, creatine supplementation, and insulin sensitization can reverse muscle loss at any age. The earlier intervention begins, the more function is preserved.
How much protein do I need to prevent muscle loss?
Adults over 40 need 1.2 to 1.6g of protein per kilogram of body weight daily, distributed across meals with 30 to 40g per meal from leucine-rich sources. The RDA of 0.8g/kg was set to prevent deficiency, not to support muscle maintenance.
Does testosterone affect muscle mass?
Yes. Testosterone is the primary anabolic hormone for skeletal muscle. It stimulates protein synthesis, activates satellite cells, and opposes cortisol's catabolic effects. Testosterone optimization when deficiency is confirmed produces measurable improvements in mass, strength, and function.
What is sarcopenic obesity?
Sarcopenic obesity is the combination of low muscle mass and high body fat, often at normal BMI because fat has replaced muscle without significant weight change. It is the highest-risk phenotype, combining the metabolic consequences of obesity with the functional consequences of sarcopenia. Body composition testing (DEXA) identifies it.
How The Lamkin Clinic Approaches Sarcopenia
Clinical Perspective
Muscle is the organ of longevity. It is the largest glucose sink in the body, the primary reservoir of amino acids for immune function and wound healing, the mechanical stimulus that maintains bone density, and the functional capacity that determines whether you live independently or in a facility. When a patient tells me they are getting weaker, I do not accept aging as the explanation. I measure their testosterone, IGF-1, insulin sensitivity, vitamin D, and inflammatory markers. Every one of those drivers is identifiable and every one is treatable. Sarcopenia is not inevitable. It is a failure to identify and treat its causes.
Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma
At The Lamkin Clinic, sarcopenia is evaluated through comprehensive hormonal assessment (free testosterone, IGF-1, DHEA-S), metabolic evaluation (fasting insulin, HOMA-IR, vitamin D), inflammatory markers (hs-CRP), and body composition analysis. Treatment targets each identified driver: progressive resistance training prescription, protein optimization at 1.2 to 1.6g/kg/day, hormonal restoration when deficient, insulin sensitization for anabolic resistance, vitamin D repletion, creatine supplementation, anti-inflammatory protocols, and BTL Emsculpt NEO for neuromuscular stimulation when mobility limitations prevent adequate resistance training.
Related Conditions
Longevity OptimizationMuscle preservation as the foundation of healthy aging and lifespan extension
→Low TestosteroneThe primary hormonal driver of age-related muscle loss
→AndropauseMale hormonal decline producing progressive sarcopenia
→OsteoporosisBone and muscle share hormonal and mechanical drivers. Treating one treats both.
→Insulin ResistanceProduces anabolic resistance, blunting the muscle's response to dietary protein
→Chronic InflammationInflammaging driving muscle protein breakdown through catabolic signaling
→Related Symptoms
Chronic FatigueHormonal decline and mitochondrial dysfunction producing energy decline alongside muscle loss
→Obesity and Weight ManagementSarcopenic obesity as the highest-risk phenotype masked by normal BMI
→Brain FogShared hormonal and metabolic drivers between cognitive and muscle decline
→Cognitive DeclineInsulin resistance and inflammation driving both muscle and cognitive deterioration
→Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.
Sarcopenia is the strongest predictor of functional decline and mortality. It is identifiable, measurable, and reversible.
The Lamkin Clinic evaluates sarcopenia through comprehensive hormonal, metabolic, and inflammatory assessment to identify and treat the specific drivers producing muscle loss. Schedule a consultation.
Schedule a ConsultationMedical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.